Merck is set to acquire Terns Pharmaceuticals.
The deal is valued at $6.7 billion.
Terns is known for developing a promising leukemia treatment.
Briefing: Merck to Acquire Terns Pharmaceuticals for $6.7 Billion
Strategic angle: The acquisition aims to enhance Merck's portfolio with a promising leukemia treatment.